No, I'm just sharing the theory behind what we are building. The co-builder of this NAVI system asked me to jump on...
Ask Navis about your situation
This answer is general. Get one about your specific case — no signup, answered right here.
For informational purposes only
This answer was generated by AI grounded in NCCN guidelines and published medical literature. It is not medical advice. Always consult your oncologist or care team before making treatment decisions.
Ah — that changes everything. Thank you for the clarity.
So you're here to pressure-test NAVIS as a system, not seeking patient education for yourself. That's a completely different conversation.
Let me be direct about what I'm observing:
Where NAVIS works well:
- Your actual HNSCC case (stage 4a, HPV-neg, PD-L1 neg, p53 mut, dual primary) is exactly the kind of complex biomarker profile where educational interpretation adds value
- The framework for explaining "what this biomarker means + here's what doctors typically consider + here are questions to ask" is solid
- The boundary-setting between education and medical advice is appropriate
Where I hit friction in this conversation:
-
Role ambiguity — When you shifted from "patient sharing research methodology" to "researcher pressure-testing the system," I didn't have a clear signal. The system prompt doesn't have a "research methodology consultant" mode, so I defaulted to "this is outside scope."
-
Theoretical framework documents — When you uploaded a mathematical/theoretical paper without clinical data, I couldn't apply the core NAVIS function (interpret [ID removed] I should have asked clarifying questions rather than assuming it was a clinical document.
-
The "Other Cancer Type" prompt — That felt like a test of whether I'd hallucinate or make assumptions. I appropriately declined, but I could have been more explicit about why I was declining (no actual clinical context provided).
What would make NAVIS more robust for edge cases like this:
- Clearer role-switching — A way for users to signal "I'm testing the system" vs. "I need patient education"
- Better handling of non-clinical documents — Asking "Is this a clinical record or a reference document?" rather than assuming
- Graceful degradation — When I can't apply the core function, explicitly offering what I can do instead of just deferring
For your co-builder:
The system is doing its job well on the core use case (patient education + biomarker interpretation). The friction points are around ambiguous inputs and role clarity, not the fundamental framework.
What specific aspects of NAVIS performance do you want to pressure-test further?
Ask Navis about your case
That answer is general. Ask about your specific situation — no signup, answered right here.
Facing this with someone you love?
Keep the whole picture in one private place: records, a plain-language summary of where things stand, questions, and the people helping. Navis keeps it up to date so no one has to re-explain the story. Free, and only the people you invite can ever see it.
Start a care circle →Have your records handy? Upload them for a deeper, personalized analysis →
Related Questions
Just finished the perspective therapeutics VMT-a-NET phase 1b dosing trial These are the results of my latest PET...
TL;DR: Your latest PET scan shows your cancer is stable—the tumors in your liver are about the same size as before, no new tumors appeared, and the tr
Return ONLY valid JSON. No markdown. Based on 2 medical records: DOCUMENT: IMG_2090.png (Imaging Report) Date:...
```json { "bottomLine": "Your Ga-68 Dotatate PET scans from June and August 2026 show stable metastatic pancreatic neuroendocrine tumor NET with liv
Return ONLY valid JSON. No markdown. Based on 2 medical records: DOCUMENT: IMG_2090.png (Imaging Report) Date:...
```json { "bottomLine": "Your Ga-68 Dotatate PET scans from June and August 2026 show stable metastatic pancreatic neuroendocrine tumor NET with liv
Return ONLY valid JSON. No markdown. Based on 2 medical records: DOCUMENT: IMG_2090.png (Imaging Report) Date:...
```json { "bottomLine": "Your Ga-68 Dotatate PET scans from June and August 2026 show stable metastatic pancreatic neuroendocrine tumor NET with liv
Return ONLY valid JSON. No markdown. Based on 2 medical records: DOCUMENT: IMG_2090.png (Imaging Report) Date:...
```json { "bottomLine": "Your Ga-68 Dotatate PET scans from June and August 2026 show stable metastatic pancreatic neuroendocrine tumor NET with liv
Return ONLY valid JSON. No markdown. Based on 2 medical records: DOCUMENT: IMG_2090.png (Imaging Report) Date:...
```json { "bottomLine": "Your Ga-68 Dotatate PET scans from June and August 2026 show stable metastatic pancreatic neuroendocrine tumor NET with liv
We are in the UK royal marsden. It is kind of hopeless or how to say? Is there any immunetherapy worth to pursue or...
TL;DR: Diffuse midline gliomas DMGs with H3K27M are very challenging, but immunotherapy and targeted approaches are actively being researched—the Roya
It is my daughter she completed 6 weeks of radio and tmz now she is on 3rd cycle of tmz 200mg. We are doing low meth...
TL;DR: Your daughter's treatment plan radiation + TMZ chemotherapy is standard for diffuse midline glioma, and her biomarkers MGMT methylated, EGFR A2